Raymond James Keeps Their Buy Rating on Ocular Therapeutix (OCUL)

Raymond James analyst Dane Leone maintained a Buy rating on Ocular Therapeutix (OCULResearch Report) yesterday. The company’s shares closed last Wednesday at $17.57.

According to TipRanks.com, Leone is a 5-star analyst with an average return of 16.3% and a 62.5% success rate. Leone covers the Healthcare sector, focusing on stocks such as Adverum Biotechnologies, Tarsus Pharmaceuticals, and Allogene Therapeutics.

Currently, the analyst consensus on Ocular Therapeutix is a Strong Buy with an average price target of $28.25.

See today’s analyst top recommended stocks >>

Based on Ocular Therapeutix’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $5.88 million and GAAP net loss of $11.94 million. In comparison, last year the company earned revenue of $829K and had a GAAP net loss of $18.78 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline include Dextenza, OTX-TP, and OTX-TIC . The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.